- Home
- LDTC vs ANTX Comparison
LDTC vs ANTX Comparison
Compare LDTC & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- ANTX
- Stock Information
- Founded
- LDTC 2007
- ANTX 2017
- Country
- LDTC Canada
- ANTX United States
- Employees
- LDTC N/A
- ANTX N/A
- Industry
- LDTC Blank Checks
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- LDTC Finance
- ANTX Health Care
- Exchange
- LDTC Nasdaq
- ANTX Nasdaq
- Market Cap
- LDTC 37.5M
- ANTX 38.5M
- IPO Year
- LDTC N/A
- ANTX 2022
- Fundamental
- Price
- LDTC $0.43
- ANTX $1.25
- Analyst Decision
- LDTC Buy
- ANTX Buy
- Analyst Count
- LDTC 2
- ANTX 4
- Target Price
- LDTC $3.00
- ANTX $3.50
- AVG Volume (30 Days)
- LDTC 170.7K
- ANTX 56.7K
- Earning Date
- LDTC 05-13-2025
- ANTX 05-13-2025
- Dividend Yield
- LDTC N/A
- ANTX N/A
- EPS Growth
- LDTC N/A
- ANTX N/A
- EPS
- LDTC N/A
- ANTX N/A
- Revenue
- LDTC $331,997.00
- ANTX N/A
- Revenue This Year
- LDTC $906.25
- ANTX N/A
- Revenue Next Year
- LDTC $149.88
- ANTX N/A
- P/E Ratio
- LDTC N/A
- ANTX N/A
- Revenue Growth
- LDTC 141.86
- ANTX N/A
- 52 Week Low
- LDTC $0.22
- ANTX $0.87
- 52 Week High
- LDTC $2.75
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- LDTC 46.01
- ANTX 44.74
- Support Level
- LDTC $0.36
- ANTX $1.18
- Resistance Level
- LDTC $0.42
- ANTX $1.33
- Average True Range (ATR)
- LDTC 0.07
- ANTX 0.08
- MACD
- LDTC 0.01
- ANTX -0.00
- Stochastic Oscillator
- LDTC 37.34
- ANTX 57.89
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation. The company generates the majority of its revenue from France, Canada, and the United states.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.